licensing agreement

Biocept will offer patient data from its liquid biopsy tests to Prognos, who will apply artificial intelligence to ensure that patients receive correct therapies. 

The pharma and biotech company said it plans to use the genome editing technology in its bioproduction products and services and in stem cells for research.

Under the agreement, Expedeon will give Quanterix access to its CaptSure immunoassay products along with its Lightning-Link antibody labeling technology.

DefiniGen said it plans to use ERS Genomics' technology to create disease models to support drug discovery for type 2 diabetes and other conditions.

DefiniGen said it plans to use the Broad's technology to create disease models to support the development of therapeutics for metabolic diseases.

CoPrimers use a proprietary chemistry that attaches primers to probes with a polyethylene glycol-based linker, which prevents the formation of primer-dimers.

Luminex has licensed the XCR Diagnostics Xtreme Chain Reaction nucleic acid amplification technology for an undisclosed amount.

The novel technology uses DNA-barcoded antibodies to enable single-cell RNA sequencing platforms to detect and quantify protein expression.

Teleflex will use Arcis' nucleic acid sample preparation chemistry to develop a rapid diagnostic assay based on RNA detection.

New England Biolabs is using Avacta's affimers with a development-stage research and diagnostic assay that could launch as early as next year.